Хронические воспалительные поражения кишечника и серонегативные спондилоартриты

1. <div><p>Harrison's Principles of Internal Medicine. 15 th ed. Mac Graw-Hill, 2002, 2, 1687</p><p>De Vlain K., Mielants H., Cuvelier C. etal. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J. Rheumatol., 2000, 27, 2860-2865</p><p>Mielants H., Vfeys E.M., Cuvelier C. et al. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin. Rheumatol., 1996,10,147-164</p><p>Grillet B., De Clerck L.t Dequeker J. et al. Systematic ileo- colonoscopy and bowel biopsy in spondylarthropathy. Br. J. Rheumatol., 1987, 26, 33 S-340</p><p>Simenon G., Vhn Gossum A., Adler M. et al. Macroscopic and microscopic gut lesions in seronegative spondylarthropathies. J. Rheumatol., 1990, 7, 491-494</p><p>Leirisalo-Repo М., Turunen U., Stenman S. et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Artr. Rheum., 1994,37, 23-31</p><p>Lee Y.H., Ji J.D., Kim J.S. et al. Ileocolonoscopic and histological studies in Korean patients with ankylosing spondylitis. Scand.J. Rheumatol., 1997,26,473-476</p><p>Mielants H., Vfeys E.M., Goemaere S. et al. Gut inflammation in the spondylarthropathies: Clinical, radiologic, biologic and genetic features in relation to the type of histology: Aprospective study. J. Rheumatol., 1991, 18, 1542-1551</p><p>Mielants H., Vfeys E.M., Cuvelier C. et al. The evolution of spondylarthropathies in relation to gut histology: Part III. Prospective study of the clinical evolution of spondylarthropathies in relation to the evolution of gut histology. J. Rheumatol., 1995, 22, 2279-2284</p><p>Mielants H., De Vfos М., Cuvelier C., Vfeys E.M. The role of gut inflammation in the pathogenesis of spondyloarthropathies. Acta Clin. Belg., 1996, 51, 5, 340-349</p><p>Mielants H., Vfeys E.M., Cuvelier C. etal. The evolution of spondylarthropathies in relation to gut histology: II. Role of the presence and type of gut inflammation in the evolution of the spondylarthropathies. J. Rheumatol., 1995, 22, 2273-2278</p><p>De Keyser F., Elewaut D., De bs M. et al. Bowel inflammation and the spondylarthropathies. Rheum. Dis. Clin. North. Am., 1998,24, 4, 785-813</p><p>Lamarque D., NhieuJ.T, Breban M. et al. Lymphocytic infiltration and expression of inducible Nitric Oxide Synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondulitis. J. Rheumatol., 2003, 30, 11, 2428-2436</p><p>Vbsiliauskas Е.А,, Kam L.Y., Karp L.C. etal. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut, 2000, 47, 487-496</p><p>Ruemmele F.M., Targan S.R., LevyG. Diagnostic accuracu of serological assays in pediatric inflammatory bowel disease. Gastroenterol., 1998,115,822-829</p><p>HofTman I.A., Demetter P., Peeters M. et al. Anli- Saccharomyces cenevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Artr. Rheum. Dis., 2003,62, 455-459</p><p>Demetter P., Baeten D., De Keyser F. et al. Subclinical gut inflammation in s pondyloarthropathy patients is associated with upregulation of the E-cadhrin/catenin complex. Artr. Rheum. Dis., 2000,59,211-216</p><p>Van Damme N., Elewaut D. etal. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alpha E beta 7 integrin. Clin. Exp. Rheumatol., 2001, 19, 618-687</p><p>Demetter P., DeVbsM., Van Damme N. et al. Focal upregulation of E- cadhrin/catenin complex in inflamed bowel mucosa but reduced expression in ulcer- associated cell lineage. Am.J.CIin.Pathol., 2000, 114, 364-370</p><p>Elewaut D., De Keyser F., Cuvelier C. et al. Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. J. Gastroenterol., 1998, 33, 743- 748</p><p>Maghraoui A.E., Dougaados М., Freneaux E. et al. Concordance between abdominal scintigraphy using tech- netium-99m hexamethylpropylene amine oxime-labclled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease. Rheumatol., 1999, 38, 543-546</p><p>Bjarnason 1., MacPherson A., Hollander D. Intestinal permeability: an overview. Gastroenterol., 1995, 108 (5), 1566-1581</p><p>Maxtom D.B., Bjarnason 1., Reynolds A.P. et al. Lactulose, slCr-EDTA and polyethylene glycol 400 probe markers in vivo assessment of human inteswinal permeability. Clin. Sci., 1986, 71,71-80</p><p>Liu Y., Xu B., Cai X. The role of intestinal permeability in the pathogenesis of ankylosing spondylitis. Zhonghua Nei Ke Za Zhi., 1995, 34 (2), 91-94</p><p>Smith M.D., Gibson R.A., Brooks P.M. Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis. J. Rheumatol., 1985, 12(2), 299-305</p><p>Martinez-Gonzalez О. Cantero-Hinojosa J., Paule-Sastre P. et al. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. Br. J. Rheumatol., 1994, 33(7), 644-647</p><p>Morris A.J. Howden C.W., Robertson C. et al. Increased intestinal permeability in ankylosing spondylitis-primary lesion or drug effect? Gut, 1991,32(12), 1470-1472</p><p>Mielants H., De Vbs М., Goemaere S. et al. Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Roleofdis- ease. J. Rheumatol., 1991,18,3, 394-400</p><p>Busch J., Hammer М., Brunkhorst R. et al. Determination of endotoxin in inflammatory rheumatic diseases - the effect of nonsteroidal anti-inflammatory agents on intestinal permeability. Z. Rheumatol., 1988, 47(3), 156-160</p><p>Deventer S.J., Gate J.W., Tytgat G.N. et al. Intestinal endotox- emia: clinical significance. Gastroenterol., 1988, 94, 825-831</p><p>Мухин H.A., ГуляёвС.В. Кривошеев О.Г. с соавт. Клиническое и прогностическое значение поражения желудочнокишечного тракта при системных сосудистых пурпурах. Тер.архив., 2003, 2, 50-54</p><p>TaurogJ.D., RichardsonJ.A., Croft J.T.etal. Thegermfreestate prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med., 1994, 180, 2359-2364</p><p>Van Damme N., De Vos М., Baeten D. et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Thl cytokine profile in spondyloarthropathy. Ann. Rheum. Dis., 2001,60,495-499</p><p>Ebringer A. Ankylosing spondylitis is caused by Klebsiella. Rhem. Dis. Clin. North. Am., 1992,18, 105-121</p><p>Maki-lkola O., Lehtinen K., Granfors K. et al. Bacterial antibodies in ankylosing spondylitis. Clin. Exp. Immunol,, 1991, 84, 472-475</p><p>Maki-lkola O., Leirisalo-Repo М., Turunen U. et al. Association of gut inflammation with increased serum IgA class Klebsiella antibody concentrations in patients with axial ankylosing spondylitis (AS): implication for different aetiopathogenetic mechanisms for axial and peripheral AS? Ann. Rheum. Dis., 1997, 56(3), 180-183.</p><p>Stebbings S., Munro K., Simon M.A. et al. Comparison of th faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatol. (Oxford)., 2002,41(12), 1395-1401</p><p>Duchmann R., Kaiser I., Hermann E. et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin. Exp. Immunol., 1995, 102(3), 448-455</p><p>Муравьев Ю.В., Лебедева B.B., Мазо B.K., Гмошинский И.В. Проницаемость защитного барьера кишечника у больных ревматическими заболеваниями, длительно получающих нестероидные противовоспалительные препараты. Клин. Фарм. Тер., 2003., 12(1), 23-26</p><p>Creemers М.С., V^n Riel P.L., Franssen M.J. et al. Second-line treatment in seronegative spondyloarthropathies. Semin. Arthr. Rheum.,1994,24,71-81</p></div><br />